GlassScriptPhysician profile
Sneha Vellala
NPI 1063876035
$2,692.83
in general payments reported to CMS, 2019-2025
19 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.86 · 2020: $278 · 2021: $743 · 2022: $526 · 2023: $534 · 2024: $402 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $917.00 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $336.17 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.88 | 2019-2025 | Xifaxan |
| Abbvie INC. | $265.25 | 2021-2023 | Teflaro |
| Astrazeneca Pharmaceuticals LP | $132.25 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $130.64 | 2021-2025 | Ultomiris |
| Inari Medical, INC. | $109.07 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $96.04 | 2022-2023 | Camzyos |
| Amgen INC. | $81.22 | 2023-2024 | Repatha |
| Melinta Therapeutics, LLC | $56.10 | 2021-2022 | |
| Smith+Nephew, INC. | $51.51 | 2022 | |
| Recor Medical INC | $50.90 | 2024 | Paradise Renal Denervation System |
| Scpharmaceuticals INC. | $33.27 | 2024 | |
| Janssen Scientific Affairs, LLC | $30.36 | 2023 | Xarelto |
| Pfizer INC. | $26.84 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.73 | 2020 | |
| Bioxcel Therapeutics, INC. | $15.73 | 2023 | Igalmi |
| Tetraphase Pharmaceuticals, INC. | $15.72 | 2020 | |
| Biomerieux INC | $8.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Vellala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.